JB Pharma stock hits 52-week high following stellar Q1 earnings report

Open Demat A/C

JB Pharma shares surge nearly 3% to 52-Week high of ₹1,999 on strong Q1 earnings

Open Demat A/C

JB Pharma revenue crosses ₹1,000 crore for the first time, up 12% YoY in Q1 FY25

Open Demat A/C

JB Pharma domestic sales rise 22% YoY, driving Q1 revenue growth despite flat international sale

Open Demat A/C

JB Pharma EBITDA grows 20% YoY to ₹292 crore, EBITDA margin expands to 29% in Q1

Open Demat A/C

JB Pharma net profit up 25% YoY to ₹177 crore, boosted by strong operational and revenue performance

Open Demat A/C

JB Pharma forecasts operating margins of 26-28%, focuses on cost optimization

Open Demat A/C

JB Pharma aims for India and CDMO business to contribute 75-80% of revenue in mid-term

Open Demat A/C

JB Pharma projects market-beating growth for India business, Targeting 60% share of chronic therapies

Open Demat A/C

With Our Subscription Plans

Open demat account in 5 minutes*

Open Demat A/C
G-L92HWH8MZR